FAQs

1. General information

The initiative will launch in September 2025 and run through the end of the year.

Berlin offers ideal conditions for this initiative:

  • 6M+ people
  • 800+ trials active
  • 400+ indications
  • 100+ active sites

In addition, the new Medical Research Act (Medizinforschungsgesetz) makes Germany even more attractive for clinical trials. Better Together Berlin will help sponsors boost awareness, accelerate enrollment, and optimize site performance in one of Europe’s most dynamic cities.

We plan to publish high-level, aggregated insights on reach, engagement, and enrollment – useful for sponsors and policymakers alike. The level of detail and access to initiative data will depend on the sponsor package chosen.

We are currently focused on proving the concept in Berlin. Once we have data-driven success, we’ll evaluate expansion. The United States is a strong candidate, especially its large metropolitan areas – stay tuned!

2. Participation & visibility

Once your participation is confirmed, we will coordinate directly with you to collect your logo, preferred link, and short description.

Your logo will be featured on the official initiative website under the supporters/partners section, along with other leading institutions committed to improving clinical trial access in Berlin.

Sponsors: There are different sponsorship and partnership levels available for sponsors and CRO (e.g., Platinum, Gold, Silver tiers), depending on the visibility and involvement you would like. See section packages.

We are happy to discuss the best fit for you individually.

Sites, HCP, Advocacy Groups, Affiliates: Its free of charge, but you should support the iniative to make it successful.

Our data shows that regional and protocol overlap reduces cost-per-patient significantly. This initiative boosts trial density and patient options. Ultimately, investigators decide which protocol to enroll a patient in – whether part of a joint campaign or not. With higher awareness and shared activation, everyone benefits.

Yes – reach out to explore future readiness, joint visibility, or site network development in Berlin.

Get in touch

3. Site network & capacity

Through our ClinLife® platform, we coordinate site capacity in real time. Each site defines how many referrals it can handle – and we match that accordingly.

Once pre-screened, patients can register on ClinLife®. Matching patients are referred directly to your site via our secure ClinLife® Investigator Portal, where your team can follow up and schedule visits.

We use indication-specific pre-screening criteria and digital workflows to ensure that only eligible, motivated patients are referred to sites.

Each referred patient comes via the GDPR compliant ClinLife® Investigator Portal with a structured profile including all answers from the online indication screener, allowing the site to assess fit quickly and reduce screen-outs.

We will collaborate with Berlin-based medical professionals. If you’re interested in sharing study awareness or becoming a referral partner, we’d love to hear from you.

4. Regulatory & operational framework

No additional EC approval. Here’s why:
  • The awareness campaign is not study-specific and therefore requires no additional EC approval.
  • Pre-screening happens on indication level, not protocol level – again, no additional EC approval needed.
  • The study details page uses already approved patient-facing materials, so no additional EC approval is required.This reduces overhead for study teams to a bare minimum.

Have more questions?

If you want to learn more about the project, please contact us.
Get in touch